111 related articles for article (PubMed ID: 18330698)
1. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.
Jannuzzo MG; Di Salle E; Spinelli R; Pirotta N; Buchan P; Bello A
Breast Cancer Res Treat; 2009 Feb; 113(3):491-9. PubMed ID: 18330698
[TBL] [Abstract][Full Text] [Related]
2. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
3. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
4. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
Dellapasqua S; Gray KP; Munzone E; Rubino D; Gianni L; Johansson H; Viale G; Ribi K; Bernhard J; Kammler R; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Colleoni M;
J Clin Oncol; 2019 Feb; 37(5):386-395. PubMed ID: 30589600
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
7. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
[TBL] [Abstract][Full Text] [Related]
8. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
Şendur MA; Aksoy S; Akıncı MB; Ozdemir N; Dede DŞ; Altundag K; Zengin N; Yalçın B
Future Oncol; 2015; 11(6):905-7. PubMed ID: 25760972
[No Abstract] [Full Text] [Related]
9. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
Frampton JE
Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573
[TBL] [Abstract][Full Text] [Related]
10. The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.
Tkalia IG; Vorobyova LI; Grabovoy AN; Svintsitsky VS; Tarasova TO
Exp Oncol; 2015 Mar; 37(1):30-5. PubMed ID: 25804228
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.
Arriagada R; Lê MG; Spielmann M; Mauriac L; Bonneterre J; Namer M; Delozier T; Hill C; Tursz T
Ann Oncol; 2005 Mar; 16(3):389-96. PubMed ID: 15677625
[TBL] [Abstract][Full Text] [Related]
12. Evaluating triptorelin as a treatment option for breast cancer.
Ferraro E; Trapani D; Marrucci E; Curigliano G
Expert Opin Pharmacother; 2019 Oct; 20(15):1809-1818. PubMed ID: 31500470
[No Abstract] [Full Text] [Related]
13. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
[TBL] [Abstract][Full Text] [Related]
15. The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers.
Martinetti A; Ferrari L; Celio L; Mariani L; Miceli R; Zilembo N; Di Bartolomeo M; Toffolatti L; Pozzi P; Seregni E; Bombardieri E; Bajetta E
J Steroid Biochem Mol Biol; 2000 Dec; 75(1):65-73. PubMed ID: 11179910
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus.
Brunner HI; Silva CA; Reiff A; Higgins GC; Imundo L; Williams CB; Wallace CA; Aikawa NE; Nelson S; Klein-Gitelman MS; Rose SR
Arthritis Rheumatol; 2015 May; 67(5):1377-85. PubMed ID: 25676588
[TBL] [Abstract][Full Text] [Related]
17. Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure.
Cohen I; Tepper R; Figer A; Flex D; Shapira J; Beyth Y
Breast Cancer Res Treat; 1999 May; 55(2):119-25. PubMed ID: 10481939
[TBL] [Abstract][Full Text] [Related]
18. Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor.
Tkalia IG; Vorobyova LI; Grabovoy AN; Svintsitsky VS; Tarasova TO; Lukyanova NY; Todor IN; Chekhun VF
Exp Oncol; 2014 Sep; 36(3):184-90. PubMed ID: 25265352
[TBL] [Abstract][Full Text] [Related]
19. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Rivera E; Valero V; Francis D; Asnis AG; Schaaf LJ; Duncan B; Hortobagyi GN
Clin Cancer Res; 2004 Mar; 10(6):1943-8. PubMed ID: 15041710
[TBL] [Abstract][Full Text] [Related]
20. The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Bajetta E; Zilembo N; Noberasco C; Martinetti A; Mariani L; Ferrari L; Buzzoni R; Greco M; Bartoli C; Spagnoli I; Danesini GM; Artale S; Paolini J
Eur J Cancer; 1997 Apr; 33(4):587-91. PubMed ID: 9274439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]